CA3117983A1 - Pharmaceutical formulations for subcutaneous administration - Google Patents

Pharmaceutical formulations for subcutaneous administration Download PDF

Info

Publication number
CA3117983A1
CA3117983A1 CA3117983A CA3117983A CA3117983A1 CA 3117983 A1 CA3117983 A1 CA 3117983A1 CA 3117983 A CA3117983 A CA 3117983A CA 3117983 A CA3117983 A CA 3117983A CA 3117983 A1 CA3117983 A1 CA 3117983A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
levodopa
carbidopa
compound
stable liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3117983A
Other languages
English (en)
French (fr)
Inventor
Ehab MOUSSA
Matthew ROSEBRAUGH
Feroz Jameel
Nancy SEVER
Maurizio F. FACHERIS
Weining Z. ROBIESON
Charles S. Locke
Sven STODTMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA3117983A1 publication Critical patent/CA3117983A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3117983A 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration Pending CA3117983A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862767546P 2018-11-15 2018-11-15
US62/767,546 2018-11-15
US201962843945P 2019-05-06 2019-05-06
US62/843,945 2019-05-06
US201962863113P 2019-06-18 2019-06-18
US201962863101P 2019-06-18 2019-06-18
US201962863093P 2019-06-18 2019-06-18
US62/863,101 2019-06-18
US62/863,093 2019-06-18
US62/863,113 2019-06-18
US201962898214P 2019-09-10 2019-09-10
US62/898,214 2019-09-10
PCT/US2019/061626 WO2020102628A1 (en) 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration

Publications (1)

Publication Number Publication Date
CA3117983A1 true CA3117983A1 (en) 2020-05-22

Family

ID=68835352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3117983A Pending CA3117983A1 (en) 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration

Country Status (14)

Country Link
US (3) US12251365B2 (enExample)
EP (1) EP3880210A1 (enExample)
JP (2) JP2022507528A (enExample)
KR (1) KR20210091139A (enExample)
CN (1) CN113015531A (enExample)
AU (2) AU2019379806B2 (enExample)
BR (1) BR112021009353A2 (enExample)
CA (1) CA3117983A1 (enExample)
IL (1) IL282842A (enExample)
MX (1) MX2021005776A (enExample)
SG (1) SG11202104499RA (enExample)
TW (1) TW202031265A (enExample)
UY (1) UY38473A (enExample)
WO (1) WO2020102628A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38473A (es) 2018-11-15 2020-06-30 Abbvie Inc Formulaciones farmacéuticas para una administración subcutánea
AU2022352845A1 (en) * 2021-10-27 2024-04-11 Abbvie Inc. Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US3939253A (en) 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US3891696A (en) 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US3998799A (en) 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US4035507A (en) 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4065566A (en) 1975-04-17 1977-12-27 Interx Research Corporation N-Nicotinoyl-3,4-dinicotinoyloxy-L-phenylalanine and derivatives pharmaceutical compositions and methods containing same
US4163058A (en) 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5874468A (en) * 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
AU1457299A (en) 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
CA2490626A1 (en) 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Prodrug, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
CN1845728B (zh) 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
JP5160786B2 (ja) 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
WO2005041925A2 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
US7342131B2 (en) 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
ES2402552T3 (es) 2004-07-06 2013-05-06 Abbott Laboratories Profármacos de inhibidores de proteasa de VIH
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EP1959948B1 (en) 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
RU2484815C2 (ru) 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
KR20090033871A (ko) 2006-06-16 2009-04-06 솔베이 파마슈티칼스 비. 브이 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
TW200843732A (en) 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
AU2009211028B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
RU2559083C9 (ru) 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
KR101868326B1 (ko) 2010-03-04 2018-06-19 오리온 코포레이션 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
CA2801917C (en) 2010-06-03 2017-04-25 Abbvie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
CN110123743A (zh) 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
CA2818161A1 (en) 2010-12-02 2012-06-07 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
RU2677278C2 (ru) 2013-03-13 2019-01-16 Неуродерм Лтд Способ лечения болезни паркинсона
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
MX393568B (es) * 2014-10-21 2025-03-24 Abbvie Inc Profarmacos de carbidopa y l-dopa y metodos de uso
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2019515908A (ja) 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
US20240024338A1 (en) 2016-04-20 2024-01-25 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
EP3487843A1 (en) 2016-07-22 2019-05-29 Syngenta Participations AG Microbiocidal oxadiazole derivatives
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
UY38473A (es) 2018-11-15 2020-06-30 Abbvie Inc Formulaciones farmacéuticas para una administración subcutánea
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
AU2022352845A1 (en) 2021-10-27 2024-04-11 Abbvie Inc. Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease

Also Published As

Publication number Publication date
BR112021009353A2 (pt) 2021-11-23
TW202031265A (zh) 2020-09-01
EP3880210A1 (en) 2021-09-22
AU2019379806B2 (en) 2025-08-14
US20250186382A1 (en) 2025-06-12
AU2019379806A1 (en) 2021-05-27
MX2021005776A (es) 2021-07-02
AU2025256148A1 (en) 2025-11-13
US12251365B2 (en) 2025-03-18
US20200155578A1 (en) 2020-05-21
US20250325507A1 (en) 2025-10-23
KR20210091139A (ko) 2021-07-21
SG11202104499RA (en) 2021-05-28
WO2020102628A1 (en) 2020-05-22
IL282842A (en) 2021-06-30
CN113015531A (zh) 2021-06-22
UY38473A (es) 2020-06-30
JP2022507528A (ja) 2022-01-18
JP2024174894A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
US20250177292A1 (en) Method for treatment of parkinson's disease
US20250325507A1 (en) Pharmaceutical formulations for subcutaneous administration
JP6889231B2 (ja) レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
RU2607497C2 (ru) Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
EP2298281B1 (en) Infusion and injection solution of Levodopa
CN106413754A (zh) 多巴脱羧酶抑制剂组合物
WO2018154447A1 (en) Dopa decarboxylase inhibitor compositions
JP2025072496A (ja) ジスキネジア治療薬
JP2024541978A (ja) 進行期パーキンソン病のためのホスレボドパ／ホスカルビドパ皮下投与治療
JP2021519272A5 (enExample)
JP2021519272A (ja) 神経変性障害の治療のための医薬組成物の継続投与
HK40055589A (en) Pharmaceutical formulations for subcutaneous administration
US12161612B2 (en) Methods and compositions for reducing symptoms of Parkinson's disease
EP4694877A1 (en) Methods and compositions for reducing symptoms of parkinson's disease
HK40012262A (zh) L-多巴、多巴脱羧酶抑制剂、儿茶酚-0-甲基转移酶抑制剂及其组合物的连续施用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241011

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250313

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260309

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309